Non-gastrointestinal stromal tumours soft tissue sarcomas: an update (2019)
- Authors:
- Autor USP: CASTRO JUNIOR, GILBERTO DE - FM
- Unidade: FM
- DOI: 10.3332/ecancer.2019.958
- Subjects: SARCOMA; NEOPLASIAS DE TECIDOS MOLES; CÉLULAS ESTROMAIS; CÉLULAS-TRONCO; CÉLULAS DA MEDULA ÓSSEA
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Ecancermedicalscience
- ISSN: 1754-6605
- Volume/Número/Paginação/Ano: v. 13, article ID 958, 16p, 2019
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
MATOS, Gustavo Duarte Ramos et al. Non-gastrointestinal stromal tumours soft tissue sarcomas: an update. Ecancermedicalscience, v. 13, 2019Tradução . . Disponível em: https://doi.org/10.3332/ecancer.2019.958. Acesso em: 28 mar. 2024. -
APA
Matos, G. D. R., Camargo, V. P. de, Munhoz, R. R., & Castro Junior, G. de C. (2019). Non-gastrointestinal stromal tumours soft tissue sarcomas: an update. Ecancermedicalscience, 13. doi:10.3332/ecancer.2019.958 -
NLM
Matos GDR, Camargo VP de, Munhoz RR, Castro Junior G de C. Non-gastrointestinal stromal tumours soft tissue sarcomas: an update [Internet]. Ecancermedicalscience. 2019 ; 13[citado 2024 mar. 28 ] Available from: https://doi.org/10.3332/ecancer.2019.958 -
Vancouver
Matos GDR, Camargo VP de, Munhoz RR, Castro Junior G de C. Non-gastrointestinal stromal tumours soft tissue sarcomas: an update [Internet]. Ecancermedicalscience. 2019 ; 13[citado 2024 mar. 28 ] Available from: https://doi.org/10.3332/ecancer.2019.958 - Diagnóstico de mutações ativadoras do gene EGFR em adenocarcinomas pulmonares: caracterização e implicações clínicas
- Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-Positive NSCLC: primary efficacy results from the ASCEND-8 study
- Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
- Manual de oncologia torácica
- Lung Cancer in Brazil [Editorial]
- Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: health-related quality-of-life results from KEYNOTE-048
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Noções de oncologia torácica
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- Pembrolizumab alone or with chemotherapy for recurrent/metastatic had and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by programmed death Ligand-1 combined positive score
Informações sobre o DOI: 10.3332/ecancer.2019.958 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas